HAE · XBRL financial data

Haemonetics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (HAE's year ends in late March)

In millions of dollars	FY 2021Apr 3, 2021	FY 2022Apr 2, 2022	FY 2023Apr 1, 2023	FY 2024Mar 30, 2024	FY 2025Mar 29, 2025	FY 2026Mar 28, 2026
Revenue from contracts with customers	—	993	1,169	1,309	1,361	1,334
Cost of goods and services sold	473	488	554	618	612	546
Gross profit	398	506	615	692	749	788
Research and development	33	47	50	54	63	60
Selling, general and administrative	274	340	377	432	437	442
Total operating expenses	308	425	459	527	527	631
Operating income (loss)	90	81	156	165	222	157
Interest expense	9	6	13	20	36	19
Other income (expense)	(17)	(17)	(15)	(13)	(10)	(29)
Income tax expense (benefit)	(7)	20	26	34	44	31
Net income (loss)	79	43	115	118	168	97
Earnings per share, basic USD per share	1.57	0.85	2.27	2.32	3.33	2.06
Earnings per share, diluted USD per share	1.55	0.84	2.24	2.29	3.31	2.05
Weighted average shares, basic millions of shares	51	51	51	51	50	47
Weighted average shares, diluted millions of shares	51	51	51	51	51	47

Fiscal years (HAE's year ends in late March)

In millions of dollars	FY 2021Apr 3, 2021	FY 2022Apr 2, 2022	FY 2023Apr 1, 2023	FY 2024Mar 30, 2024	FY 2025Mar 29, 2025	FY 2026Mar 28, 2026
Cash and cash equivalents	192	259	284	179	307	245
Accounts receivable	128	159	179	207	203	217
Inventory	323	293	259	317	365	306
Prepaid and other current assets	51	44	47	66	60	66
Total current assets	694	756	770	769	935	835
Property and equipment, net	218	258	311	311	284	306
Right-of-use asset	60	53	53	55	47	40
Goodwill	466	467	466	565	604	656
Total assets	1,820	1,860	1,935	2,196	2,451	2,396
Accounts payable	50	58	64	73	67	51
Current portion of long-term debt	17	214	12	10	304	5
Total current liabilities	253	442	252	300	578	283
Long-term debt	691	559	754	798	921	1,220
Lease liability, non-current	63	56	56	58	50	41
Retained earnings	158	202	253	360	352	279
Total stockholders' equity	732	749	818	960	821	796
Total liabilities and equity	1,820	1,860	1,935	2,196	2,451	2,396
Common shares outstanding (cover page) millions of shares	51	51	51	51	48	45

Fiscal years (HAE's year ends in late March)

In millions of dollars	FY 2021Apr 3, 2021	FY 2022Apr 2, 2022	FY 2023Apr 1, 2023	FY 2024Mar 30, 2024	FY 2025Mar 29, 2025	FY 2026Mar 28, 2026
Net income (loss)	79	43	115	118	168	97
Stock-based compensation	26	24	26	28	30	34
Net cash from operating activities	109	172	273	182	182	293
Purchases of property and equipment	37	97	110	66	39	33
Net cash from investing activities	(425)	(86)	(144)	(322)	(162)	(180)
Share repurchases	0	0	75	0	225	175
Repayments of long-term debt	22	18	10	12	5	—
Net cash from financing activities	367	(16)	(100)	38	109	(178)
Net change in cash	55	67	25	(106)	128	(61)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Haemonetics	223	339	52	45.5M	Q1 FY27 10-QJun 27, 2026
Teleflex	300	570	not reported	42.4M	Q2 FY26 10-QJun 30, 2026
LivaNova	563	393	74*	55.1M	Q3 FY26 10-QSep 30, 2026
Envista Holdings	1,159	692	78*	160.3M	Q3 FY26 10-QOct 2, 2026
Enovis	13	583	75*	57.7M	Q2 FY26 10-QJul 3, 2026
Ufp Technologies	9	174	16*	7.7M	Q2 FY26 10-QJun 30, 2026
Lemaitre Vascular	27	not reported	16*	22.9M	Q2 FY26 10-QJun 30, 2026
AtriCure	187	154	not reported	50.9M	Q3 FY26 10-QSep 30, 2026
Dentsply Sirona	239	898	99*	199.4M	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.